Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)

CAPS Rating: 4 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar BACnumber1 (< 20) Submitted: 5/15/2011 1:43:51 AM : Outperform Start Price: $2.29 AEZS Score: -77.61

cheap healthcare!

Report this Post Reply

Featured Broker Partners


Advertisement